BILLERICA, Mass.– Nirrin Technologies, a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.
“Greg brings 30 years of strategic leadership in life science and biomanufacturing, and a long-standing history in commercializing industry-first tools and technologies,” said Matt Gunnison, CEO of Gamma Biosciences, a Nirrin strategic investor. “His track record of commercial successes and driving revenue growth sets a strong foundation for Nirrin as the company enters the commercialization phase for its high-precision tunable laser spectroscopy™ (HPTLS) platform.”
Greg most recently led Kytopen as its Chief Commercial Officer, where he effectively drove the commercial strategy to accelerate their non-viral gene delivery platform developed at MIT. Prior to that, Greg served as Enterprise Delivery Leader for the Cell & Gene Therapy business at Cytiva (formerly GE Healthcare Life Sciences), where he helped build out the Enterprise Solutions business, including delivery of the industry’s first flexible manufacturing platforms for biomanufacturing. While at Cytiva he also served as Business Leader for Cell Culture Services, Xcellerex and Microcarriers, launching flagship products and quadrupling revenue.
“Early evaluators of Nirrin’s HPTLS platform have validated its potential to completely disrupt how bioprocess scientists get excipient and protein data on their drug formulations. Typical time to answer can take weeks. Using our platform, early evaluators are getting actionable results in real time. I’m excited to see how our new STEP program partners utilize the HPTLS platform to speed time to answer in their own bioprocesses,” said Greg Crescenzi, CEO of Nirrin. “I am thrilled to partner with our founder and CTO, Bryan Hassell along with the entire Nirrin team to bring our breakthrough technologies to the biopharma market.”
Greg has also held business leadership, sales and marketing roles at key industry leaders including BD Biosciences, Pall Life Sciences and Millipore Corporation.
